<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1862">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01660321</url>
  </required_header>
  <id_info>
    <org_study_id>SPN-109-11</org_study_id>
    <nct_id>NCT01660321</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation</brief_title>
  <official_title>A Single Treatment, Pharmacokinetic (PK) and Tolerance Study of Natroba (Spinosad) Topical Suspension, 0.9% in Pediatric Subjects 6 Months to 4 Years of Age With an Active Head Lice Infestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ParaPRO LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ParaPRO LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pharmacokinetic and tolerance study of Natroba (spinosad) Topical Suspension, 0.9% in
      pediatric subjects 6 months to 4 years of age with an active head lice infestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Postmarketing Requirement Protocol, multicenter, open-label study in pediatric subjects 6
      months to 4 years of age with an active head lice infestation designed to determine the
      topical absorption and safety of Natroba (spinosad) Topical Suspension, 0.9% for a single,
      10 minute treatment for spinosad (Spinosyn A and Spinosyn D) and benzyl alcohol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Cmax for Spinosyn A</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Spinosyn A</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-12) for Spinosyn A</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Spinosyn D</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Spinosyn D</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-12) for Spinosyn D</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Benzyl Alcohol</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 μg/mL) in Natroba (spinosad) Topical Suspension, 0.9%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Benzyl Alcohol</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-12) for Benzyl Alcohol</measure>
    <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Pediculosis</condition>
  <arm_group>
    <arm_group_label>Natroba</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spinosad</intervention_name>
    <description>A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.</description>
    <arm_group_label>Natroba</arm_group_label>
    <other_name>Natroba (spinosad) Topical Suspension, 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 6 months to 4 years of age.

          2. Subjects must have had an active lice infestation including live lice.

          3. Individuals in otherwise good general health, free of any systemic or dermatologic
             disorders which, in the opinion of the Principal Investigator or designee, would
             interfere with the study results or increase the risk of adverse events.

          4. A parent (or guardian) must have signed an Informed Consent Form to allow any child
             to participate in the study.

          5. Subjects must have been available to stay in the clinic for blood draws. Parents or
             guardians must have been available to stay in the clinic, with the subject, for the
             entire duration of the study.

          6. Subjects must have had veins capable of insertion of a Heplock catheter or
             withstanding multiple blood draws as determined by the Principal Investigator or
             qualified phlebotomist.

          7. Normal values (at screening) for serum chemistry and hematology for subjects, unless
             the principal Investigator or qualified medical designee determined that the abnormal
             value was not clinically significant.

        Exclusion Criteria:

          1. History of irritation or sensitivity to pediculicide or hair care products or
             ingredients.

          2. History of known allergy or sensitivity to topical anesthetics including lidocaine
             and prilocaine.

          3. History of allergy or sensitivity to Heparin.

          4. Systemic diseases that could have interfered with the results of this study as
             determined by the Principal Investigator or designee.

          5. Any condition or illness that, in the opinion of the Investigator or designee, may
             have compromised the objective of the protocol or the safety of the subject.

          6. The use of antibiotics or other systemic medications within 2 weeks of the screening
             visit, which in the opinion of the Investigator or designee could have interfered
             with the outcome of the study.

          7. Participation in a previous drug study within the past 30 days.

          8. Individuals with any visible skin/scalp condition (other than from an active lice
             infestation) at the treatment site which would have interfered with the evaluations
             according to the opinion of the Investigator or designee.

          9. Parents or guardians who, in the opinion of the Investigator, did not understand
             their child's requirements for study participation and/or may be likely to exhibit
             poor compliance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dowling B Stough, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Burke Pharmaceutical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey C Seiler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lice Solutions Resource Network, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lice Solutions Resource Network, Inc.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 16, 2012</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <firstreceived_results_date>August 20, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediculosis capitis</keyword>
  <keyword>Head Lice</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall Study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Natroba</title>
          <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natroba</title>
          <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2" spread="0.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Spinosyn A</title>
        <description>Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol. For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples. Therefore, Cmax, Tmax, and AUC 0-12 were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax for Spinosyn A</title>
            <description>Peak Plasma Concentration of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%</description>
            <units>ng/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Spinosyn A</title>
        <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol. For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples. Therefore, Cmax, Tmax, and AUC 0-12 were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax for Spinosyn A</title>
            <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn A.</description>
            <units>hours</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-12) for Spinosyn A</title>
        <description>Area under the plasma concentration versus time curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol. For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples. Therefore, Cmax, Tmax, and AUC 0-12 were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC (0-12) for Spinosyn A</title>
            <description>Area under the plasma concentration versus time curve (AUC) of Spinosyn A in Natroba (spinosad) Topical Suspension, 0.9%.</description>
            <units>ng*hr/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Spinosyn D</title>
        <description>Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol. For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples. Therefore, Cmax, Tmax, and AUC 0-12 were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax for Spinosyn D</title>
            <description>Peak Plasma Concentration of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%</description>
            <units>ng/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Spinosyn D</title>
        <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol. For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples. Therefore, Cmax, Tmax, and AUC 0-12 were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax for Spinosyn D</title>
            <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for Spinosyn D.</description>
            <units>hours</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-12) for Spinosyn D</title>
        <description>Area under the plasma concentration versus time curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol. For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples. Therefore, Cmax, Tmax, and AUC 0-12 were not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC (0-12) for Spinosyn D</title>
            <description>Area under the plasma concentration versus time curve (AUC) of Spinosyn D in Natroba (spinosad) Topical Suspension, 0.9%.</description>
            <units>ng* hr/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">For all but 1 subject (Subject 02-202), all spinosyn A and spinosyn D concentrations were Below Quantification Level (BQL) or &lt; 3.0 ng/mL for all samples.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Benzyl Alcohol</title>
        <description>Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 μg/mL) in Natroba (spinosad) Topical Suspension, 0.9%.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax for Benzyl Alcohol</title>
            <description>Peak Plasma Concentration of benzyl alcohol (above Limit of Quantitation (1.0 μg/mL) in Natroba (spinosad) Topical Suspension, 0.9%.</description>
            <units>μg/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.123" spread="0.3071" lower_limit="0.5" upper_limit="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Benzyl Alcohol</title>
        <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax for Benzyl Alcohol</title>
            <description>The time after administration of Natroba (spinosad) Topical Suspension, 0.9% when the maximum plasma concentration is reached for benzyl alcohol.</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.3071" lower_limit="0.5" upper_limit="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-12) for Benzyl Alcohol</title>
        <description>Area under the plasma concentration versus time curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%.</description>
        <time_frame>Blood samples collected up to 12 hours post treatment - 0 (pre-treatment), 0.5, 1.0, 3.0, 6.0 and 12 hours post-treatment.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Since the only benzyl alcohol concentrations above Limit of Quantitation (LOQ) (1.0 μg/mL) were for 1 sample each for 4 subjects and 2 non-consecutive samples for 2 subjects, AUC (0-12) was not summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Natroba</title>
            <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC (0-12) for Benzyl Alcohol</title>
            <description>Area under the plasma concentration versus time curve (AUC) of benzyl alcohol in Natroba (spinosad) Topical Suspension, 0.9%.</description>
            <units>μg*hr/mL</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Since the only benzyl alcohol concentrations above LOQ (1.0 μg/mL) were for 1 sample each for 4 subjects and 2 non-consecutive samples for 2 subjects, AUC 0-12 was not summarized.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study.</time_frame>
      <desc>All Adverse Events (AEs)occurring during the study were recorded at 0 (pretreatment), 0.5, 1, 3, 6, and 12 hours post-treatment by age group and all subjects. Verbatim descriptions of AEs were assigned to system organ classes and preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA) (v14.0).</desc>
      <group_list>
        <group group_id="E1">
          <title>Natroba</title>
          <description>Natroba (Spinosad) Topical Suspension, 0.9%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It is suspected for Subject 02-202, at 0.5 hours, the sample to determine the spinosyn A and spinosyn D concentrations were possibly contaminated with Natroba.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Quality and Regulatory</name_or_title>
      <organization>ParaPro</organization>
      <phone>317-810-6205</phone>
      <email>kerrym@parapro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
